Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (VISNU-2)

April 10, 2019 updated by: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Randomized Phase II Study to Explore the Influence of BRAF and PIK3K Status on the Efficacy of FOLFIRI Plus Bevacizumab or Cetuximab, as First Line Therapy of Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells

The purpose of the study is to explore the influence of BRAF and PIK3K status on the efficacy of FOLFIRI plus Bevacizumab or Cetuximab, as first line therapy of patients with RAS wild-type metastatic colorectal carcinoma and < 3 circulating tumor cells

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

240

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Madrid, Spain, 28046
        • Spanish Cooperative Group for Digestive Tumour Therapy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patient's Informed consent in written.
  2. Age between 18-70 years old.
  3. ECOG 0-1.
  4. Life expectancy of at least 3 months.
  5. Histological confirmation of adenocarcinoma of the colon or rectum.
  6. Sample of tumour tissue available for evaluation of genes RAS, BRAF and PI3K. To be included in the study patients should present < 3 CTC in peripheral blood and RAS wild-type present in the sample of tumor tissue.
  7. Measurable metastatic stage IV disease with at least 1 measurable metastatic lesion following RECIST criteria v 1.1 (non suitable for radical surgery at the inclusion time).
  8. Prior radiotherapy is allowed but must be completed at least 4 weeks before randomization (if applicable).
  9. Adequate bone marrow, liver and renal function.
  10. Women of childbearing potential must have a negative serum or urine pregnancy test. Postmenopausal women must have been amenorrheic for at least 12 months.Both men and women participating in this study must use adequate contraception.
  11. Subject must have the ability, in the opinion of the investigator, to comply with all the study procedures and follow-up examinations.

Exclusion Criteria:

  1. Previous chemotherapy for metastatic disease.
  2. Prior treatment with Bevacizumab, or EGFR inhibitors
  3. Any anticancer treatment (chemotherapy, hormonal treatment, radiation treatment, surgery , immunotherapy, biologic therapy or tumour embolization) within 4 weeks before randomization.
  4. Use of any investigational drug within 4 weeks before start the treatment.
  5. Clinical or radiographic evidence of brain metastasis.
  6. Uncontrolled hypertension (systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg on repeated measurement) despite optimal medical management.
  7. Previous history of hypertensive encephalopathy or hypertensive crises.
  8. Current or history of peripheral neuropathy > or equal to 1 NCICTCAE.
  9. Patients classified as fragile according to criteria listed in the protocol.
  10. Significant cardiovascular disease (e.g. AVC, myocardial infarction, within 6 months before randomization). Unstable angina, congestive heart failure New York Heart Association (NYHA) ≥ class II, arrhythmia that requires treatment within 3 months before randomization.
  11. Significant vascular disease (e.g. aortic aneurism requiring surgical intervention, pulmonary embolic, peripheral arterial thrombosis) within 6 months before randomization.
  12. Previous history of significant haemorrhage /severe, within 1 month before randomization.
  13. Major surgery, open surgical biopsy or significant traumatic injury within 4 weeks before randomization.
  14. Large bore needle biopsy of a major organ within 14 days before randomization. Placement of central venous access port > or equal to 7 days before randomization is permitted.
  15. Evidence or history of bleeding diathesis or coagulopathy.
  16. INR >1.5 within 14 days prior to starting study treatment. EXEMPTION: patients on full anticoagulation must have an in-range INR[usually between 2-3]. Any anticoagulation therapy must be at stable dosing prior to enrolment.
  17. History of previous abdominal fistula or gastrointestinal perforation within 6 months before randomization.
  18. Serious non-healing wound, ulcer or bone fracture.
  19. Acute or sub-acute of intestinal occlusion or history of intestinal inflammatory disease.
  20. History of uncontrolled convulsive crises.
  21. History of pulmonary fibrosis, acute lung disease or interstitial pneumonia.
  22. Chronic, actual o recent use (10 days prior first drug administration) of acetylsalicylic acic (aspirin) > 325 mg/day or clopidogrel (75mg/day) or other treatments that can cause gastrointestinal ulcer (low-dose aspirin is permitted < or equal to 325 mg/day).
  23. Urinary protein excretion > or equal to 2+ (dipstick). If > or equal 2 g proteinuria is detected with dipstick, a 24-hour period urine test will be performed and the result should be < or equal to 1 g/24 hours to permit the inclusion of the patient in the clinical trial
  24. Known human immunodeficiency virus infection or chronic hepatitis B or C infection or other uncontrolled, severe concurrent infection .
  25. Current infection > or equal to Grade 2 (NCI-CTCAE).
  26. Any previous or concurrent cancer different to colorectal carcinoma within 5 years before to start the treatment. Subjects with successfully treated, non-invasive cancers, including cervical cancer in situ, basal cell carcinoma will be allowed to participate in the clinical trial. Or those cancer treated with curative intention without disease evidence in the last 5 years at least
  27. Known or suspected allergy or hypersensitivity to any component of bevacizumab, cetuximab, irinotecan, or 5-FU/LV.
  28. Any medical, psychological, or social condition that may interfere with the subject's participation in the study or evaluation of the study results.
  29. Any psychological, familial or geographic situation that interferes in the adequate follow-up and adherence to the study protocol.
  30. Women who are pregnant or breast-feeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: A
FOLFIRI+bevacizumab
Drug: FOLFIRI + bevacizumab
  • Bevacizumab 5 mg/kg iv, followed by
  • Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by
  • Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by
  • 5-FU 400 mg/m2 iv bolus, followed by
  • 5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).
EXPERIMENTAL: B
FOLFIRI + cetuximab
Drug: FOLFIRI + cetuximab
  • Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly

  • FOLFIRI:

    • Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by
    • Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by
    • 5-FU 400 mg/m2 iv bolus, followed by
    • 5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
progression free survival (PFS)
Time Frame: 5 years
5 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Overall survival (OS)
Time Frame: 5 years
5 years
Adverse events
Time Frame: 5 years
5 years
Response rate (RR)
Time Frame: 5 years
5 years
Radical Resection (R0) surgery rate
Time Frame: 5 years
5 years
Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)
Time Frame: 5 years
5 years
CTC count basal and correlate to PFS, OS, RR
Time Frame: 5 years
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Collaborators

Roche Pharma AG

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 1, 2012

Primary Completion (ACTUAL)

November 1, 2018

Study Completion (ACTUAL)

November 1, 2018

Study Registration Dates

First Submitted

June 13, 2012

First Submitted That Met QC Criteria

July 10, 2012

First Posted (ESTIMATE)

July 13, 2012

Study Record Updates

Last Update Posted (ACTUAL)

April 11, 2019

Last Update Submitted That Met QC Criteria

April 10, 2019

Last Verified

August 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TTD-12-02
  • 2012-000840-90 (EUDRACT_NUMBER)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Colorectal Cancer Metastatic

Clinical Trials on FOLFIRI + bevacizumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe